Cetirizine does not influence the immune response.
Antihistamines are frequently employed in the treatment of allergic rhinitis and urticaria-angioedema syndrome. We analyzed the in vitro effects of cetirizine on the immune response. To this end the proliferation of peripheral mononuclear cells induced by mitogen and by -CD3, -CD2, or -CD28 monoclonal antibodies has been studied. Since the plasma peak of cetirizine following ingestion of 10 mg is about 1 microgram/mL, the drug was tested in the cultures at the concentration of 0.1, 1, or 10 micrograms/mL. No influence of cetirizine on T cell proliferation was detected. We also evaluated the effect of cetirizine on the expression of the following markers expressed by T cells upon activation: lymphocyte markers ICAM-1, HLA-DR, and CD25 surface expression, alpha-1-acid glycoprotein has been also studied. There was no effect of cetirizine on the investigated immunologic parameters; these data acquire clinical relevance when related to previous reports showing a depression of the immunologic response exerted by other compounds such as ketotifen and theophylline and when related to the recent data about the modulation of ICAM-1 expression on eosinophils by cetirizine. Cetirizine does not affect ICAM-1 expression of lymphocyte membrane.
Canonica
G W
GW
Allergy and Clinical Immunology Service, Department of Internal Medicine Genoa, Italy.
Pesce
G
G
Ruffoni
S
S
Buscaglia
S
S
Boero
F
F
Jing
G
G
Rihoux
J P
JP
Ciprandi
G
G
D000328:Adult; D000911:Antibodies, Monoclonal / Q000276:immunology; D000917:Antibody Formation / Q000187:drug effects*; D015703:Antigens, CD / Q000276:immunology; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D018106:CD28 Antigens; D017252:CD3 Complex; D015704:CD4 Antigens / Q000276:immunology; D015815:Cell Adhesion Molecules / Q000032:analysis; D002455:Cell Division / Q000187:drug effects; D017332:Cetirizine; D004305:Dose-Response Relationship, Drug; D005260:Female; D006684:HLA-DR Antigens / Q000032:analysis; D006634:Histamine H1 Antagonists / Q000097:blood / Q000627:therapeutic use*; D000949:Histocompatibility Antigens Class II / Q000032:analysis; D006801:Humans; D006919:Hydroxyzine / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D018799:Intercellular Adhesion Molecule-1; D007665:Ketotifen / Q000494:pharmacology; D008297:Male; D008934:Mitogens / Q000494:pharmacology; D009961:Orosomucoid / Q000032:analysis; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D015375:Receptors, Interleukin-2 / Q000032:analysis; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D013806:Theophylline / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D018106:CD28 Antigens; D017252:CD3 Complex; D015704:CD4 Antigens; D015815:Cell Adhesion Molecules; D006684:HLA-DR Antigens; D006634:Histamine H1 Antagonists; D000949:Histocompatibility Antigens Class II; D008934:Mitogens; D009961:Orosomucoid; D011948:Receptors, Antigen, T-Cell; D015375:Receptors, Interleukin-2; D018799:Intercellular Adhesion Molecule-1; D006919:Hydroxyzine; D013806:Theophylline; D007665:Ketotifen; D017332:Cetirizine